Cirillo, Melita, Craig, Alexander F. M., Borchmann, Sven and Kurtz, David M. (2020). Liquid biopsy in lymphoma: Molecular methods and clinical applications. Cancer Treat. Rev., 91. OXFORD: ELSEVIER SCI LTD. ISSN 1532-1967

Full text not available from this repository.

Abstract

In this article, we broadly review the application of cfDNA analysis to the diagnosis and management of lymphoma. We introduce the advantages of cfDNA measurement over conventional tissue biopsy and describe how cfDNA may be utilized for both genotyping and detection of minimal residual disease. First, we discuss genotyping, beginning with differences in identifying mutations from the blood plasma vs. from circulating cells. We review the technical distinctions between PCRand NGS-based assays and describe two important applications of NGS-based cfDNA tests, namely the identification of resistance mutations and classification of disease subtype. We discuss difficulties in genotyping diseases with low burden of tumor cells and the application of cfDNA assays in these contexts. Second, we describe the utility of ctDNA measurement in assessing MRD. We cover recent advances in the assessment of pre-treatment disease burden as a prognostic biomarker, detection of molecular response to therapy, and early detection of relapsing disease. Third, we explore select emerging areas of research in ctDNA technologies that show promise in boosting the performance of existing ctDNA-based assays. These include cell-free DNA fragment structure analysis or 'fragmentomics', epigenetic modifications, and novel circulating analytes such as tumor-educated platelets and extracellular vesicular DNA. We also discuss alternative analytes to blood plasma for tumor detection, such as urine, saliva, and stool. Finally, we present a case that highlights potential applications of ctDNA approaches to the management of patients with lymphoma, while also defining important prerequisite advances before this can be fully realized. We close with a look to the future of cfDNA applications, outlining one potential timeline and path forward towards routine clinical application.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Cirillo, MelitaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Craig, Alexander F. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, SvenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kurtz, David M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-310287
DOI: 10.1016/j.ctrv.2020.102106
Journal or Publication Title: Cancer Treat. Rev.
Volume: 91
Date: 2020
Publisher: ELSEVIER SCI LTD
Place of Publication: OXFORD
ISSN: 1532-1967
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
B-CELL LYMPHOMA; CIRCULATING TUMOR DNA; INTERIM PET-CT; GENE-EXPRESSION; PLASMA DNA; INDEPENDENT PREDICTOR; RESIDUAL DISEASE; CANCER; HODGKINS; HYPOMETHYLATIONMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/31028

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item